Benzinga's M&A Chatter for Thursday June 6, 2013

The following are the M&A deals, rumors and chatter circulating on Wall Street for Thursday June 6, 2013: SodaStream Shares Soar to $100 in Pre-Market on Rumored Pepsi Bid The Rumor:
Shares of SodaStream SODA traded as high as $100 early in the pre-market session on a report from the Israeli website Calcalist that PepsiCo PEP was in talks to acquire the maker of home carbonation systems. Pepsi CEO Indra Nooyi told Bloomberg that she had not heard about the talks with SodaStream and later told CNBC that there was no truth to the rumor. A spokesperson for SodaStream declined comment. SodaStream closed at $71.24 Thursday, a gain of 2.73% on 6 times average volume. Crest Urges Clearwire Board to Consider DISH Tender Offer The Shareholder Letter:
Clearwire CLWR shareholder Crest Financial sent a letter to Clearwire's Board of Directors criticizing Sprint Nextel's objections to DISH Network's $4.40 per share tender offer for Clearwire shares. Crest agreed with DISH that Sprint's letter was "fraught with unfounded assertions." Crest's General Counsel, David K. Schumacher, said Sprint made no attempt to explain how its current offer of $3.40 can possibly be fair to minority stockholders while DISH is offering $4.40 per share. Crest urged Clearwire's Board to appoint a new Special Committee to consider DISH's tender offer. Clearwire closed at $4.28 Thursday, a loss of $0.04 on lower than average volume. Royalty Pharma Extends Deadline for Increased Offer for Elan The Offer Extension:
Royalty Pharma announced Thursday that the closing date for its Increased Offer for Elan Corporation ELN is being extended until 8:00 AM ET on Friday, June 21 2013. Royalty Pharma offered $12.50 per share for Elan on May 20. That offer was rejected by Elan's board. In related news, the Irish Takeover Panel ruled that Royalty Pharma must lapse its offer for Elan if any of the resolutions being put to Elan's Extraordinary General Meeting on June 17, 2013 are passed. The Panel also ruled that Royalty Pharma's proxy statement breached the Irish Takeover Rules, which vindicates Elan's decision to seek injunctive relief from the Irish High Court earlier this week restraining the distribution of the proxy statement. Elan closed at $12.68 Thursday, a gain of $0.03 on higher than average volume.